Day 1,941: tirzepatide, voracious
Novo Nordisk, maker of semaglutide, branded Ozempic for diabetes and Wegovy for weight loss, and Eli Lilly, which makes tirzepatide, a more effective alternative, have together added around $1trn in market value since 2021.
With over two-fifths of the world overweight or obese, demand for glp-1 drugs is voracious.
Artwork of the day
Greed
Leonor_FiniOriginal Title:La GourmandiseDate:1929
Word of the day
tirzepatide: a drug C225H348N48O68 that selectively binds to and activates cell receptors for glucagon-like peptide 1 and gastric inhibitory polypeptide acting to stimulate insulin secretion, decrease glucagon secretion, and delay gastric emptying and that is administered by injection for the management of type 2 diabetes or for the promotion of weight loss in obese patients or in overweight patients with a comorbidity
NOTE: Tirzepatide is marketed under the trademarks Mounjaro and Zepbound.
voracious: very eager for something, especially a lot of food:
Quote of the day
“I'm a real self-educated kind of guy. I read voraciously. Every book I ever bought, I have. I can't throw it away. It's physically impossible to leave my hand! Some of them are in warehouses. I've got a library that I keep the ones I really really like. I look around my library some nights and I do these terrible things to myself--I count up the books and think, how long I might have to live and think, 'F@#%k, I can't read two-thirds of these books.' It overwhelms me with sadness."
--David Bowie, quoted in the Daily Beast in a 2002 interview with Bob Guccione, Jr.”
― David Bowie